Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Revvity Omics, |
RCV001783200 | SCV002022190 | pathogenic | Vici syndrome | 2021-11-08 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV001783200 | SCV002783083 | pathogenic | Vici syndrome | 2024-06-04 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001783200 | SCV004539090 | pathogenic | Vici syndrome | 2024-08-05 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg955*) in the EPG5 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in EPG5 are known to be pathogenic (PMID: 23222957, 23674064). This variant is present in population databases (rs761554022, gnomAD 0.0009%). This premature translational stop signal has been observed in individual(s) with Vici syndrome (PMID: 28615637). ClinVar contains an entry for this variant (Variation ID: 1322825). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |